Saturday, February 16, 2019
Home Clinical Trial Updates

Clinical Trial Updates

Killing Cancer Cells by Shining a Light on a Rare Metal

Iridium –  a very hard, brittle, second-densest silvery-white transition metal of the platinum group, is a found in meteorites in a much higher abundance than in the Earth's crust. As a result, the unusually high abundance of iridium in the clay layer at the Cretaceous–Paleogene boundary resulted in the Alvarez hypothesis, which suggest that the impact of a massive extraterrestrial...

Electromagnetic Navigation Bronchoscopy Shows Positive Response In Lung Cancer Study

An analysis of 12-month results from NAVIGATE, the largest, prospective, multicenter trial designed to evaluate outcomes following electromagnetic navigation bronchoscopy™ (ENB™) procedures using Medtronic's superDimension™ navigation system, shows positive results. Electromagnetic navigation bronchoscopy™ is a minimally invasive technology that guides endoscopic tools to pulmonary lesions.  The technology has been evaluated primarily in small, single-center studies. NAVIGATE enrolled subjects at 37...

Study Confirms Complication Rates and Costs for Drugs and Diagnostics Higher in Lung Cancer

According to a new study from The University of Texas MD Anderson Cancer Center, complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials. The procedures were also associated downstream average costs ranging from U.S. $ 6,320 to U.S. $ 56,845. In the study,...

INmune Bio Receives Phase I Clinical Trial Authorization for Lead Product in Ovarian Cancer

INmune Bio, a clinical-stage biotechnology company developing anti-cancer therapies to reprogram the innate immune system to fight disease, has received Clinical Trial Authorization (CTA) by the United Kingdom regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA), for a Phase I clinical trial of its lead therapeutic candidate INKmune™. The innate immune drug will be used to treat relapsed and...

Rakuten Aspyrian Raises US $284 Million Series C Financing; Develops Photoimmunotherapy Platform

Privately funded clinical stage biotechnology company Rakuten Aspyrian has raised an additional $134 million in a second tranche of its Series C financing, bringing the total amount raised to $284 million. New investors include the SBI Group, Japan and Rakuten. As a result, Rakuten Aspyrian has raised approximately US $ 372 million in equity since the company's founding in...

Daiichi Sankyo Initiates Phase I Study to Evaluate the Combination Quizartinib and Milademetan

A first patient has been dosed in the first novel-novel combination phase I study evaluating two investigational agents being developed by Daiichi Sankyo. The phase I study will evaluate the safety and activity of the combination quizartinib, an oral selective type II FLT3 inhibitor, and milademetan (DS-3032), an oral selective MDM2 inhibitor, in patients with relapsed/refractory FLT3-ITD acute myeloid leukemia...

Phase III ARCHES Trial Shows Positive Results for Enzalutamide in Prostate Cancer

Despite improved treatment options for patients progressing on standard hormone treatment, metastatic prostate cancer still remains a deadly disease. For men with metastatic hormone-sensitive prostate cancer (mHSPC), starting standard androgen deprivation therapy (ADT), the median overall survival (OS) is approximately 45 months. However, for patients with higher-volume disease, the median survival was less (35.1 and 32.2 months, respectively). ADT has long...

Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics

Daiichi Sankyo and AnHeart Therapeutics, a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines, have entered into a worldwide exclusive license agreement to out-license DS-6051, an investigational selective ROS1/NTRK inhibitor, currently in Phase I development for the treatment of patients harboring either a ROS1 or NTRK fusion gene and neuroendocrine tumors. The trials are being...

Phase III AGENT Trial Enrolls First Metastatic Colorectal Cancer Patient

A first patient has been enrolled in the pivotal Phase III AGENT clinical study designed to evaluate arfolitixorin (Modufolin®; Isofol Medical) for the treatment of metastatic colorectal cancer (mCRC). The AGENT trial (NCT03750786) is a randomized, controlled, multi-center study with blinded independent review of the tumor response and is expected to enroll approximately 440 mCRC patients, who are at least...

Oxybutynin Improved Quality of Life for Breast Cancer Survivors

Treatment with oxybutynin chloride (Ditropan XL®; Janssen Pharmaceuticals) helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a study presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX. the study was funded by the Breast...

right side

ads

Related articles